Summit Therapeutics PLC (SMMT) has disclosed a new risk, in the Debt & Financing category.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Summit Therapeutics PLC is exposed to material going-concern risk, as its existing cash, cash equivalents, and short-term investments are insufficient to fund planned operations for the twelve months following issuance of its March 31, 2026 unaudited financial statements. The company’s reliance on uncertain external financing heightens the prospect of operational cutbacks, program delays, or an eventual cessation of activities if capital cannot be raised on acceptable terms.
The average SMMT stock price target is $31.25, implying 93.92% upside potential.
To learn more about Summit Therapeutics PLC’s risk factors, click here.